EyePoint (EYPT) Net Margin (2010 - 2026)
EyePoint (EYPT) posted Net Margin of 17270.26% for Q1 2026, down 58.37% sequentially from 10904.68% in Q4 2025, and down 1705591.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) Net Margin (2010 - 2026) Analysis & Trends
EyePoint has reported Net Margin for 17 years, with the latest figure at 17270.26% in Q1 2026.
- Quarterly Net Margin fell 1705591.0% year-over-year to 17270.26% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4031.1% (down 375630.0% YoY) and the FY2025 annual result came in at 739.42%, down 43699.0% from the prior year.
- Net Margin retreated to 17270.26% in Q1 2026 per EYPT's latest filing, from 10904.68% in the prior quarter.
- Over five years, Net Margin peaked at 121.03% in Q4 2023 and troughed at 17270.26% in Q1 2026.
- A 5-year average of 2398.59% and a median of 384.7% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2026: Net Margin jumped 74030 bps in 2023, then sank 1705591 bps in 2026.
- Over 5 years, Net Margin stood at 420.54% in 2022, then surged by 71 bps to 121.03% in 2023, then tumbled by 195 bps to 357.26% in 2024, then plunged by 2952 bps to 10904.68% in 2025, then tumbled by 58 bps to 17270.26% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 17270.26%, 10904.68%, and 6183.44% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | -18,633.14% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18,633.14% |
| Mar 31, 2026 | -12,548.13% |
| Dec 31, 2025 | -10,920.81% |
| Sep 30, 2025 | -6,183.44% |
| Jun 30, 2025 | -1,114.31% |
| Mar 31, 2025 | -200.15% |
| Dec 31, 2024 | -358.12% |
| Sep 30, 2024 | -278.99% |
| Jun 30, 2024 | -325.27% |
| Mar 31, 2024 | -285.42% |
| Dec 31, 2023 | -116.42% |
| Sep 30, 2023 | -94.72% |
| Jun 30, 2023 | -254.77% |
| Mar 31, 2023 | -290.37% |
| Dec 31, 2022 | -421.37% |
| Sep 30, 2022 | -189.86% |
| Jun 30, 2022 | -172.54% |
| Mar 31, 2022 | -210.15% |
| Dec 31, 2021 | -168.38% |
| Sep 30, 2021 | -184.36% |